(Boursier.com) — METabolic Explorer announces the approval of the agreement concluded with its main partners on December 23, 2022 within the framework of the conciliation procedure and having the effect of securing the liquidities necessary to enable it to deploy its strategic plan over the period 2023-2024. In addition, METabolic Explorer is launching a capital increase with maintenance of shareholders’ preferential subscription rights (DPS) for a maximum amount of around 8 million euros.
Approval of the agreement
As part of the conciliation procedure, the homologation judgment rendered by the Commercial Court of Paris on February 7 is intended to put an end to the conciliation procedures opened for the benefit of METabolic Explorer and its subsidiaries Metex Nøøvistago and Metex Nøøvista.
To date, the main conditions precedent have all been satisfied. It is therefore anticipated that the financing provided for in the Agreement will occur concomitantly with the settlement-delivery of the new ordinary shares to be issued within the framework of the Capital Increase.
Launch of a capital increase of nearly 8 ME
In this context, METabolic Explorer is launching, on February 7, a capital increase with maintenance of preferential subscription rights for a maximum amount, issue premium included, of 7,999,998.85 euros, by issuing a maximum number of 7,079. 645 new ordinary shares (New Shares) at a unit subscription price of 1.13 euro.